(NASDAQ: ALLO) Allogene Therapeutics's forecast annual revenue growth rate of 352.37% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Allogene Therapeutics's revenue in 2024 is $95,000.On average, 5 Wall Street analysts forecast ALLO's revenue for 2024 to be $25,701,983, with the lowest ALLO revenue forecast at $16,909,199, and the highest ALLO revenue forecast at $33,818,398. On average, 3 Wall Street analysts forecast ALLO's revenue for 2025 to be $25,871,075, with the lowest ALLO revenue forecast at $16,909,199, and the highest ALLO revenue forecast at $33,818,398.
In 2026, ALLO is forecast to generate $1,804,718,831 in revenue, with the lowest revenue forecast at $33,818,398 and the highest revenue forecast at $5,343,306,947.